All In MedTech

Device Trial Radar · NCT01798407

DBS of the Lateral Habenula in Treatment-Resistant Depression

A Clinical Pilot Study Examining Bilateral Inhibition of the Lateral Habenula as a Target for Deep Brain Stimulation in Intractable Depression

Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

6

Actual

Start

Feb 2013

Primary completion

Aug 2026

Study completion Aug 2026

Sponsor

Lead sponsor
Wayne Goodman MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 25, 2013

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 21 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study will investigate the safety, tolerability, and benefit of bilateral deep brain stimulation (DBS) to the lateral habenula in subjects with treatment-resistant major depression (TRD) secondary to either nonpsychotic unipolar major depressive disorder (MDD), or bipolar disorder (BD) I. Six adult subjects with TRD will be treated in this single-site study at Baylor College of Medicine; subjects will be chronically symptomatic with significant functional disability, and will have demonstrated resistance to standard somatic and pharmacotherapeutic treatments. The primary outcome measure will be the change in the 17-item Hamilton Depression Rating Scale (HDRS\^17) six months after the commencement of stimulation.

Conditions

  • Treatment Resistant Major Depressive Disorder

Interventions

  • Activa Tremor Control Sys (DBS Implant)Device

    DBS system consists of the Activa RC 37612 System (Implantable Pulse Generator with Model 37085 Extensions (40 to 95cm), Activa Patient Programmer, and Medtronic Model 3389 DBS Lead). This system is commercially approved for the treatment of chronic, intractable Parkinson's Disease. It will be used with the Model SP-10344 Memory Mod Software which enables the physician to program the Implantable Pulse Generator to a higher frequency.

  • Randomized, staggered withdrawal phaseOther

    For responders only: double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen biweekly until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HDRS^17 score from baseline to 6 months after the commencement of stimulationTime frame: baseline, Month 6, Month 12 and 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Baylor College of Medicine

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.